The ATDC (TRIM29) protein binds p53 and antagonizes p53-mediated functions

Molecular and Cellular Biology

Volumn 30, Issue 12, 2010, Pages 3004-3015

  Yuan, Zhigang ^a   Villagra, Alejandro ^a   Peng, Lirong ^a   Coppola, Domenico ^a   Glozak, Michele ^a   Sotomayor, Eduardo M ^a   Chen, Jiandong ^a   Lane, William S ^b   Seto, Edward ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAXIA TELANGIECTASIA GROUP D COMPLEMENTING GENE; GENE PRODUCT; LYSINE; PROTEIN NOXA; PROTEIN P21; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

ACETYLATION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; EMBRYO; ENZYME REPRESSION; GENE CONTROL; GENE EXPRESSION; GENETIC ASSOCIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION;

ACETYLATION; ANIMALS; APOPTOSIS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA-BINDING PROTEINS; HCT116 CELLS; HUMANS; LYSINE; MICE; PHOSPHOSERINE; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN TRANSPORT; PROTEINS; SUBCELLULAR FRACTIONS; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

ATAXIA TELANGIECTASIA;

EID: 77953416244     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.01023-09     Document Type: Article

References (68)

1. Aizawa, H., S. C. Hu, K. Bobb, K. Balakrishnan, G. Ince, I. Gurevich, M. Cowan, and A. Ghosh. 2004. Dendrite development regulated by CREST, a calcium-regulated transcriptional activator. Science 303:197-202.
2. Basu, A., K. L. Rose, J. Zhang, R. C. Beavis, B. Ueberheide, B. A. Garcia, B. Chait, Y. Zhao, D. F. Hunt, E. Segal, C. D. Allis, and S. B. Hake. 2009. Proteome-wide prediction of acetylation substrates. Proc. Natl. Acad. Sci. U. S. A. 106:13785-13790.
3. Binkley, C. E., M. A. Davis, L. Zhang, T. S. Lawrence, C. D. Logsdon, and D. M. Simeone. 2003. The ataxia telangiectasia group D associated gene confers a cellular survival advantage in pancreatic adenocarcinoma. J. Surg. Res. 114:240.
4. Boder, E., and R. P. Sedgwick. 1958. Ataxia-telangiectasia; a familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection. Pediatrics 21:526-554.
5. Borden, K. L. 1998. RING fingers and B-boxes: zinc-binding protein-protein interaction domains. Biochem. Cell Biol. 76:351-358.
6. Brzoska, P. M., H. Chen, Y. Zhu, N. A. Levin, M. H. Disatnik, D. Mochly-Rosen, J. P. Murnane, and M. F. Christman. 1995. The product of the ataxia-telangiectasia group D complementing gene, ATDC, interacts with a protein kinase C substrate and inhibitor. Proc. Natl. Acad. Sci. U. S. A. 92:7824-7828.
7. Chen, J., V. Marechal, and A. J. Levine. 1993. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13:4107-4114.
8. 1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncogene 23:21-29.
9. Choudhary, C., C. Kumar, G. Florian, M. L. Nielsen, M. Rehman, T. Walther, J. V. Olsen, and M. Mann. 2009. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325:834-840.
10. CIP1 by c-Myc in overcoming transforming growth factor β-induced cell-cycle arrest. Proc. Natl. Acad. Sci. U. S. A. 97:9498-9503.
11. Datto, M. B., Y. Yu, and X. F. Wang. 1995. Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. J. Biol. Chem. 270:28623-28628.
12. Dyrskjot, L., M. Kruhoffer, T. Thykjaer, N. Marcussen, J. L. Jensen, K. Moller, and T. F. Orntoft. 2004. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res. 64:4040-4048.
13. Forbes, S., J. Clements, E. Dawson, S. Bamford, T. Webb, A. Dogan, A. Flanagan, J. Teague, R. Wooster, P. A. Futreal, and M. R. Stratton. 2006. COMIC 2005. Br. J. Cancer 94:318-322.
14. Gartel, A. L., and A. L. Tyner. 2002. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol. Cancer Ther. 1:639-649.
15. WAF1/CIP1 promoter and interacts with Sp1/Sp3. Proc. Natl. Acad. Sci. U. S. A. 98:4510-4515.
16. Giannakakou, P., D. L. Sackett, Y. Ward, K. R. Webster, M. V. Blagosklonny, and T. Fojo. 2000. p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat. Cell Biol. 2:709-717.
17. Glebov, O. K., L. M. Rodriguez, P. Soballe, J. DeNobile, J. Cliatt, K. Nakahara, and I. R. Kirsch. 2006. Gene expression patterns distinguish colonoscopically isolated human aberrant crypt foci from normal colonic mucosa. Cancer Epidemiol. Biomarkers Prev. 15:2253-2262.
18. Glozak, M. A., N. Sengupta, X. Zhang, and E. Seto. 2005. Acetylation and deacetylation of non-histone proteins. Gene 363:15-23.
19. Hawthorn, L., L. Stein, J. Panzarella, G. M. Loewen, and H. Baumann. 2006. Characterization of cell-type specific profiles in tissues and isolated cells from squamous cell carcinomas of the lung. Lung Cancer 53:129-142.
20. Hosoi, Y., L. N. Kapp, J. P. Murnane, Y. Matsumoto, A. Enomoto, T. Ono, and K. Miyagawa. 2006. Suppression of anchorage-independent growth by expression of the ataxia-telangiectasia group D complementing gene, ATDC. Biochem. Biophys. Res. Commun. 348:728-734.
21. Jakobi, R., C. C. McCarthy, M. A. Koeppel, and D. K. Stringer. 2003. Caspase-activated PAK-2 is regulated by subcellular targeting and proteasomal degradation. J. Biol. Chem. 278:38675-38685.
22. Kapp, L. N., and R. B. Painter. 1989. Stable radioresistance in ataxia-telangiectasia cells containing DNA from normal human cells. Int. J. Radiat. Biol. 56:667-675.
23. Kapp, L. N., R. B. Painter, L. C. Yu, N. van Loon, C. W. Richard 3rd, M. R. James, D. R. Cox, and J. P. Murnane. 1992. Cloning of a candidate gene for ataxia-telangiectasia group D. Am. J. Hum. Genet. 51:45-54.
24. Klotzsche, O., D. Etzrodt, H. Hohenberg, W. Bohn, and W. Deppert. 1998. Cytoplasmic retention of mutant tsp53 is dependent on an intermediate filament protein vimentin scaffold. Oncogene 16:3423-3434. (Pubitemid 28349685)
25. Koeppel, M. A., C. C. McCarthy, E. Moertl, and R. Jakobi. 2004. Identification and characterisation of PS-GAP as a novel regulator of caspase-activated PAK-2. J. Biol. Chem. 279:53653-53664.
26. Kosaka, Y., H. Inoue, T. Ohmachi, T. Yokoe, T. Matsumoto, K. Mimori, F. Tanaka, M. Watanabe, and M. Mori. 2007. Tripartite motif-containing 29 TRIM29 is a novel marker for lymph node metastasis in gastric cancer. Ann. Surg. Oncol. 14:2543-2549.
27. Kuribayashi, K., and W. S. El-Deiry. 2008. Regulation of programmed cell death by the p53 pathway. Adv. Exp. Med. Biol. 615:201-221.
28. LaTulippe, E., J. Satagopan, A. Smith, H. Scher, P. Scardino, V. Reuter, and W. L. Gerald. 2002. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 62:4499-4506. (Pubitemid 34827314)
29. Leonhardt, E. A., L. N. Kapp, B. R. Young, and J. P. Murnane. 1994. Nucleotide sequence analysis of a candidate gene for ataxia-telangiectasia group D ATDC. Genomics 19:130-136.
30. Li, A., Y. Xue, C. Jin, M. Wang, and X. Yao. 2006. Prediction of Nepsilonacetylation on internal lysines implemented in Bayesian discriminant method. Biochem. Biophys. Res. Commun. 350:818-824.
31. Liu, A. X., J. R. Testa, T. C. Hamilton, R. Jove, S. V. Nicosia, and J. Q. Cheng. 1998. AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. Cancer Res. 58:2973-2977.
32. Luo, J., D. J. Duggan, Y. Chen, J. Sauvageot, C. M. Ewing, M. L. Bittner, J. M. Trent, and W. B. Isaacs. 2001. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res. 61:4683-4688. (Pubitemid 32691876)
33. Morrell, D., E. Cromartie, and M. Swift. 1986. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J. Natl. Cancer Inst. 77:89-92.
34. Mutter, G. L., J. P. Baak, J. T. Fitzgerald, R. Gray, D. Neuberg, G. A. Kust, R. Gentleman, S. R. Gullans, L. J. Wei, and M. Wilcox. 2001. Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. Gynecol. Oncol. 83:177-185.
35. Nacht, M., A. T. Ferguson, W. Zhang, J. M. Petroziello, B. P. Cook, Y. H. Gao, S. Maguire, D. Riley, G. Coppola, G. M. Landes, S. L. Madden, and S. Sukumar. 1999. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res. 59:5464-5470. (Pubitemid 29526458)
36. Nikolaev, A. Y., M. Li, N. Puskas, J. Qin, and W. Gu. 2003. Parc: a cytoplasmic anchor for p53. Cell 112:29-40.
37. Oda, E., R. Ohki, H. Murasawa, J. Nemoto, T. Shibue, T. Yamashita, T. Tokino, T. Taniguchi, and N. Tanaka. 2000. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288:1053-1058.
38. Ohmachi, T., F. Tanaka, K. Mimori, H. Inoue, K. Yanaga, and M. Mori. 2006. Clinical significance of TROP2 expression in colorectal cancer. Clin. Cancer Res. 12:3057-3063.
39. Pan, Y., and J. Chen. 2003. MDM2 promotes ubiquitination and degradation of MDMX. Mol. Cell. Biol. 23:5113-5121.
40. Peng, Y., C. Li, L. Chen, S. Sebti, and J. Chen. 2003. Rescue of mutant p53 transcription function by ellipticine. Oncogene 22:4478-4487.
41. Pfaffl, M. W. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:45.
42. Reddy, B. A., L. D. Etkin, and P. S. Freemon. 1992. A novel zinc finger coiled-coil domain in a family of nuclear proteins. Trends Biochem. Sci. 17:344-345.
43. Reymond, A., G. Meroni, A. Fantozzi, G. Merla, S. Cairo, L. Luzi, D. Riganelli, E. Zanaria, S. Messali, S. Cainarca, A. Guffanti, S. Minucci, P. G. Pelicci, and A. Ballabio. 2001. The tripartite motif family identifies cell compartments. EMBO J. 20:2140-2151.
44. Riley, T., E. Sontag, P. Chen, and A. Levine. 2008. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell. Biol. 9:402-412.
45. Santin, A. D., F. Zhan, S. Bellone, M. Palmieri, S. Cane, E. Bignotti, S. Anfossi, M. Gokden, D. Dunn, J. J. Roman, T. J. O'Brien, E. Tian, M. J. Cannon, J. Shaughnessy, Jr., and S. Pecorelli. 2004. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int. J. Cancer 112:14-25.
46. Sarbassov, D. D., S. M. Ali, S. Sengupta, J. H. Sheen, P. P. Hsu, A. F. Bagley, A. L. Markhard, and D. M. Sabatini. 2006. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22:159-168.
47. Sardiello, M., S. Cairo, B. Fontanella, A. Ballabio, and G. Meroni. 2008. Genomic analysis of the TRIM family reveals two groups of genes with distinct evolutionary properties. BMC Evol. Biol. 8:225.
48. Scheffner, M., K. Munger, J. C. Byrne, and P. M. Howley. 1991. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. U. S. A. 88:5523-5527.
49. Shibata, M. A., K. Yoshidome, E. Shibata, C. L. Jorcyk, and J. E. Green. 2001. Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21. Cancer Gene Ther. 8:23-35.
50. Shieh, S.-Y., M. Ikeda, Y. Taya, and C. Prives. 1997. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325-334.
51. Smith, A. P., K. Hoek, and D. Becker. 2005. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol. Ther. 4:1018-1029.
52. Suzuki, A., H. Kawano, M. Hayashida, Y. Hayasaki, Y. Tsutomi, and K. Akahane. 2000. Procaspase 3/p21 complex formation to resist fas-mediated cell death is initiated as a result of the phosphorylation of p21 by protein kinase A. Cell Death Differ. 7:721-728. (Pubitemid 30599253)
53. Tang, Y., W. Zhao, Y. Chen, Y. Zhao, and W. Gu. 2008. Acetylation is indispensable for p53 activation. Cell 133:612-626.
54. Treier, M., L. M. Staszewski, and D. Bohmann. 1994. Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 78:787-798.
55. Tsao, Y. P., S. J. Huang, J. L. Chang, J. T. Hsieh, R. C. Pong, and S. L. Chen. 1999. Adenovirus-mediated p21WAF1/SDII/CIP1 gene transfer induces apoptosis of human cervical cancer cell lines. J. Virol. 73:4983-4990. (Pubitemid 29246759)
56. Villagra, A. V., N. Ulloa, X. Zhang, Z. Yuan, E. Sotomayor, and E. Seto. 2007. HDAC3 down-regulates cholesterol synthesis through repression of lanosterol synthase gene expression. J. Biol. Chem. 282:35457-35470.
57. Villunger, A., E. M. Michalak, L. Coultas, F. Mullauer, G. Bock, M. J. Ausserlechner, J. M. Adams, and A. Strasser. 2003. p53- and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa. Science 302:1036-1038.
58. Vousden, K. H., and C. Prives. 2009. Blinded by the light: the growing complexity of p53. Cell 137:413-431.
59. Wang, L., D. G. Heidt, C. J. Lee, H. Yang, C. D. Logsdon, L. Zhang, E. R. Fearon, M. Ljungman, and D. M. Simeone. 2009. Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization. Cancer Cell 15:207-219.
60. Wolf, D., and S. P. Goff. 2007. TRIM28 mediates primer binding site-targeted silencing of murine leukemia virus in embryonic cells. Cell 131:46-57.
61. CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene 22:351-360.
62. Yang, X. J., V. V. Ogryzko, J. Nishikawa, B. H. Howard, and Y. A. Nakatani. 1996. p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382:319-324.
63. Yang, X. J., and E. Seto. 2008. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol. Cell 31:449-461.
64. Yu, Y. P., D. Landsittel, L. Jing, J. Nelson, B. Ren, L. Liu, C. McDonald, R. Thomas, R. Dhir, S. Finkelstein, G. Michalopoulos, M. Becich, and J. H. Luo. 2004. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J. Clin. Oncol. 22: 2790-2799.
65. Yuan, Z., X. Zhang, N. Sengupta, W. S. Lane, and E. Seto. 2007. SIRT1 regulates the function of the Nijmegen breakage syndrome protein. Mol. Cell 27:149-162.
66. Zhan, F., J. Hardin, B. Kordsmeier, K. Bumm, M. Zheng, E. Tian, R. Sanderson, Y. Yang, C. Wilson, M. Zangari, E. Anaissie, C. Morris, F. Muwalla, F. van Rhee, A. Fassas, J. Crowley, G. Tricot, B. Barlogie, and J. Shaughnessy, Jr. 2002. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99:1745-1757.
67. Zhang, P., Z. Zhang, X. Zhou, W. Qiu, F. Chen, and W. Chen. 2006. Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line. BMC Cancer 6:224.
68. Zhang, Y., A. Dimtchev, A. Dritschilo, and M. Jung. 2001. Ionizing radiation-induced apoptosis in ataxia-telangiectasia fibroblasts: roles of caspase-9 and cellular inhibitor of apoptosis protein-1. J. Biol. Chem. 276:28842-28848.